首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   307065篇
  免费   17337篇
  国内免费   537篇
耳鼻咽喉   4265篇
儿科学   10548篇
妇产科学   10438篇
基础医学   46899篇
口腔科学   7683篇
临床医学   24988篇
内科学   57431篇
皮肤病学   6411篇
神经病学   21944篇
特种医学   12090篇
外国民族医学   43篇
外科学   48269篇
综合类   8032篇
现状与发展   1篇
一般理论   167篇
预防医学   20535篇
眼科学   7122篇
药学   21887篇
  28篇
中国医学   840篇
肿瘤学   15318篇
  2021年   2714篇
  2019年   2725篇
  2018年   4438篇
  2017年   3137篇
  2016年   3730篇
  2015年   4256篇
  2014年   5444篇
  2013年   8248篇
  2012年   9883篇
  2011年   9835篇
  2010年   6765篇
  2009年   6055篇
  2008年   9019篇
  2007年   9875篇
  2006年   9638篇
  2005年   9228篇
  2004年   8873篇
  2003年   8250篇
  2002年   7796篇
  2001年   13371篇
  2000年   13760篇
  1999年   11509篇
  1998年   3120篇
  1997年   2858篇
  1996年   2667篇
  1995年   2568篇
  1992年   8337篇
  1991年   8473篇
  1990年   8291篇
  1989年   8105篇
  1988年   7329篇
  1987年   7090篇
  1986年   6733篇
  1985年   6526篇
  1984年   4784篇
  1983年   4130篇
  1982年   2497篇
  1979年   4437篇
  1978年   3237篇
  1977年   2738篇
  1976年   2514篇
  1975年   2851篇
  1974年   3356篇
  1973年   3367篇
  1972年   3128篇
  1971年   2950篇
  1970年   2842篇
  1969年   2585篇
  1968年   2544篇
  1967年   2375篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).

Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.

Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).

Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).

Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.

Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED.  相似文献   
12.
13.
14.
15.
16.
17.
18.
19.
Gastro-oesophageal reflux disease (GORD) is symptomatic reflux of gastric contents into the oesophagus. Factors predisposing to GORD are loss of the physiological antireflux barrier and anatomic abnormalities of the oesophagus or diaphragm. Conservative measures and medical management results in resolution of symptoms in a majority of children. Surgery is indicated in the event of failure of medical management or severe complications. Surgical procedures include open or laparoscopic fundoplication in children with normal neurology; fundoplication with or without vagotomy and pyloroplasty; surgical feeding jejunostomy and oesophago-gastric dissociation in the severely neurologically impaired children.  相似文献   
20.
Background: Egyptian street youth use substances including tobacco, illicit drugs, and pharmaceutical drugs. To understand the circumstances, including adverse childhood experiences, that place adolescents at risk for engaging in substance use, we conducted in-depth interviews among a sample of Egyptian street children. Methods: From youth residing at or attending Caritas, a non-profit organization, which provides shelter and education to street youth, seven girls and twelve boys, aged 12–18 years, participated in open-ended, in-depth interviews. Results: Eight out of the 19 participants reported family history (early exposure) to substance use; and seven of them were initiated by either a family member (sibling), friend or coworker. Most of the participants reported a history of conflict with or abuse (verbal or physical) by their parents or siblings, or stressful situations at home; they used substance(s) to alleviate their stress. Few attended school, and some were forced to work and help their family. Conclusions: Among Egyptian youth, adverse childhood experiences, such as poverty, child abuse, and family substance use, challenge somewhat susceptible youths and lead them to the path of substance use and addiction. Prevention intervention should be multifaceted, culturally adaptable, and primarily targeting the social environment during childhood.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号